No Data
No Data
Express News | HC Wainwright & Co. Reiterates Buy on Protara Therapeutics, Maintains $23 Price Target
Oppenheimer Maintains Protara Therapeutics(TARA.US) With Buy Rating, Cuts Target Price to $25
Oppenheimer Sticks to Their Buy Rating for Protara Therapeutics (TARA)
Protara Therapeutics | 8-K: Protara Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update
Protara Therapeutics | 10-Q: Q3 2024 Earnings Report
Protara Therapeutics Reports Q3 EPS (50c), Consensus (52c)
No Data
No Data